A comprehensive review on time-tested anticancer drug doxorubicin
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
Doxorubicin or Adriamycin, is one of the most widely used chemotherapeutic drug for treating a myriad of cancers. It induces cell death through multiple intracellular targets: reactive oxygen species generation, DNA-adduct formation, topoisomerase II inhibition, histone eviction, Ca2+ and iron hemostasis regulation, and ceramide overproduction. Moreover, doxorubicin-treated dying cells undergo cellular modifications that enable neighboring dendritic cell activation and enhanced presentation of tumor antigen. In addition, doxorubicin also aids in the immune-mediated clearance of tumor cells. However, the development of chemoresistance and cardiotoxicity side effect has undermined its widespread applicability. Several formulations of doxorubicin and co-treatments with inhibitors, miRNAs, natural compounds and other chemotherapeutic drugs have been essential in reducing its dosage-dependent toxicity and combating the development of resistance. Further, more advanced research into the molecular mechanism of chemoresistance development would be vital in improving the overall survivability of clinical patients and in preventing cancer relapse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Doxorubicin pathways: pharmacodynamics and adverse effects
Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833ffb56 · Cited by 1,648
Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II
Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F. (1984) · Science · doi:10.1126/science.6093249 · Cited by 1,538
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Jonker, J. W., Buitelaar, M., Wagenaar, E., van der Valk, M. A., Scheffer, G. L., Scheper, R. J., Plösch, T., Kuipers, F., Elferink, R. P. J. O., Rosing, H., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202607599 · Cited by 822
A family of related ATP-binding subunits coupled to many distinct biological processes in bacteria
Higgins, C. F., Hiles, I. D., Salmond, G. P. C., Gill, D. R., Downie, J. A., Evans, I. J., Holland, I. B., Gray, L., Buckel, S. D., Bell, A. W., et al. (1986) · Nature · doi:10.1038/323448a0 · Cited by 755
Sledge, G. W., Neuberg, D., Bernardo, P., Ingle, J. N., Martino, S., Rowinsky, E. K., & Wood, W. C. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.013 · Cited by 707
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Tsuruo, T., Iida, H., Tsukagoshi, S., & Sakurai, Y. (1982) · PubMed · Cited by 659
Muggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.987 · Cited by 647
Davies, K. J., & Doroshow, J. H. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35746-0 · Cited by 631
Adriamycin, 14‐hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesius
Arcamone, F., Cassinelli, G., Fantini, G., Grein, A., Orezzi, P., Pol, C., & Spalla, C. (1969) · Biotechnology and Bioengineering · doi:10.1002/bit.260110607 · Cited by 622
Hahn, G. M., Braun, J., & Har-Kedar, I. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.3.937 · Cited by 480
Alizadeh, D., Trad, M., Hanke, N. T., Larmonier, C. B., Janikashvili, N., Bonnotte, B., Katsanis, E., & Larmonier, N. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1545 · Cited by 416
Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy
Ma, Y., Aymeric, L., Locher, C., Mattarollo, S. R., Delahaye, N. F., Pereira, P., Boucontet, L., Apetoh, L., Ghiringhelli, F., Casares, N., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100269 · Cited by 337
Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
Mattarollo, S. R., Loi, S., Duret, H., Ma, Y., Zitvogel, L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0753 · Cited by 333
Gorini, S., De Angelis, A., Berrino, L., Malara, N., Rosano, G., & Ferraro, E. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/7582730 · Cited by 325
A systematic analysis of FDA-approved anticancer drugs
Sun, J., Wei, Q., Zhou, Y., Wang, J., Liu, Q., & Xu, H. (2017) · BMC Systems Biology · doi:10.1186/s12918-017-0464-7 · Cited by 322
Greene, R. F., Collins, J. M., Jenkins, J., Speyer, J. L., & Myers, C. E. (1983) · PubMed · Cited by 292
Xu, J., Liu, D., Niu, H., Zhu, G., Xu, Y., Ye, D., Li, J., & Zhang, Q. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0487-8 · Cited by 283
Wilson, B. E., Jacob, S., Yap, M. L., Ferlay, J., Bray, F., & Barton, M. B. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30163-9 · Cited by 270
Doroshow, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4514 · Cited by 269
De Angelis, A., Piegari, E., Cappetta, D., Marino, L., Filippelli, A., Berrino, L., Ferreira-Martins, J., Zheng, H., Hosoda, T., Rota, M., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.895771 · Cited by 268
Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists
Yamazaki, T., Hannani, D., Poirier-Colame, V, Ladoire, S., Locher, C., Sistigu, A., Prada, N., Adjemian, S., Catani, J. P., Freudenberg, M., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.72 · Cited by 262
Membrane Topology of a Cysteine-less Mutant of Human P-glycoprotein
Loo, T. W., & Clarke, D. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.843 · Cited by 252
Engineering Biomimetic Platesomes for pH‐Responsive Drug Delivery and Enhanced Antitumor Activity
Liu, G., Zhao, X., Zhang, Y., Xu, J., Xu, J., Li, Y., Min, H., Shi, J., Zhao, Y., Wei, J., et al. (2019) · Advanced Materials · doi:10.1002/adma.201900795 · Cited by 233
Gupta, S. K., Garg, A., Bär, C., Chatterjee, S., Foinquinos, A., Milting, H., Streckfuß-Bömeke, K., Fiedler, J., & Thum, T. (2018) · Circulation Research · doi:10.1161/circresaha.117.311335 · Cited by 227
Liposomal doxorubicin (Doxil): An effective new treatment for Kaposi's sarcoma in AIDS
James, N. D., Coker, R. J., Tomlinson, D., Harris, J. R. W., Gompels, M., Pinching, A. J., & Stewart, J. S. W. (1994) · Clinical Oncology · doi:10.1016/s0936-6555(05)80269-9 · Cited by 205
Exosomal delivery of doxorubicin enables rapid cell entry and enhanced in vitro potency
Schindler, C., Collinson, A., Matthews, C., Pointon, A., Jenkinson, L., Minter, R. R., Vaughan, T. J., & Tigue, N. J. (2019) · PLOS ONE · doi:10.1371/journal.pone.0214545 · Cited by 200
Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy.
Torti, F. M., Bristow, M. R., Lum, B. L., Carter, S. K., Howes, A. E., Aston, D. A., Brown, B. W., Hannigan, J. F., Meyers, F. J., & Mitchell, E. P. (1986) · PubMed · Cited by 197
Pillai, V. B., Kanwal, A., Fang, Y. H., Sharp, W. W., Samant, S., Arbiser, J., & Gupta, M. P. (2017) · Oncotarget · doi:10.18632/oncotarget.16133 · Cited by 192
Carbonyl Reductase 1 Is a Predominant Doxorubicin Reductase in the Human Liver
Kassner, N., Huse, K., Martin, H.-J., Gödtel-Armbrust, U., Metzger, A., Meineke, I., Brockmöller, J., Klein, K., Zanger, U. M., Maser, E., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.022251 · Cited by 180
Licata, S., Saponiero, A., Mordente, A., & Minotti, G. (2000) · Chemical Research in Toxicology · doi:10.1021/tx000013q · Cited by 176
Minotti, G., Recalcati, S., Mordente, A., Liberi, G., Calafiore, A. M., Mancuso, C., Preziosi, P., & Cairo, G. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.7.541 · Cited by 173
A role for ceramide in driving cancer cell resistance to doxorubicin
Liu, Y., Yu, J. Y., Yin, D., Patwardhan, G. A., Gupta, V. K., Hirabayashi, Y., Holleran, W. M., Giuliano, A. E., Jazwinski, S. M., Gouazé‐Andersson, V., et al. (2008) · The FASEB Journal · doi:10.1096/fj.07-092981 · Cited by 170
Coenzyme Q10 for Prevention of Anthracycline-Induced Cardiotoxicity
Conklin, K. A. (2005) · Integrative Cancer Therapies · doi:10.1177/1534735405276191 · Cited by 165
The role of iron in anthracycline cardiotoxicity
Gammella, E., Maccarinelli, F., Buratti, P., Recalcati, S., & Cairo, G. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00025 · Cited by 163
Adverse Effects of Doxorubicin and Its Metabolic Product on Cardiac RyR2 and SERCA2A
Hanna, A. D., Lam, A., Tham, S., Dulhunty, A. F., & Beard, N. A. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.093849 · Cited by 163
Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1
Denard, B., Lee, C., & Ye, J. (2012) · eLife · doi:10.7554/elife.00090 · Cited by 162
Ji, C., Yang, B., Yang, Y.-L., He, S.-H., Miao, D.-S., He, L., & Bi, Z.-G. (2010) · Oncogene · doi:10.1038/onc.2010.379 · Cited by 161
Quercetin attenuates doxorubicin cardiotoxicity by modulating B mi‐1 expression
Dong, Q., Chen, L., Lu, Q., Sharma, S. P., Li, L., Morimoto, S., & Wang, G. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12795 · Cited by 158
Kiyomiya, K.-I., Matsuo, S., & Kurebe, M. (2001) · PubMed · Cited by 150
Kast, C., Canfield, V., Levenson, R., & Gros, P. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.16.9240 · Cited by 141
Chekhun, V. F., Lukianova, N. Y., Kovalchuk, O., Tryndyak, V., & Pogribny, I. P. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0663 · Cited by 131
Ding, Z.-C., Lu, X., Yu, M., Lemos, H., Huang, L., Chandler, P., Liu, K., Walters, M., Krasinski, A., Mack, M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3596 · Cited by 131
Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment
Hanks, B. A., Holtzhausen, A., Evans, K. S., Jamieson, R., Gimpel, P., Campbell, O. M., Hector-Greene, M., Sun, L., Tewari, A., George, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65745 · Cited by 120
Wali, A. F., Rashid, S., Rashid, S. M., Ansari, M. A., Khan, M. R., Haq, N., Alhareth, D. Y., Ahmad, A., & Rehman, M. U. (2020) · Plants · doi:10.3390/plants9040550 · Cited by 120
Lapatinib and doxorubicin enhance the Stat1‐dependent antitumor immune response
Hannesdóttir, L., Tymoszuk, P., Parajuli, N., Wasmer, M., Philipp, S., Daschil, N., Datta, S., Koller, J., Tripp, C. H., Stoitzner, P., et al. (2013) · European Journal of Immunology · doi:10.1002/eji.201242505 · Cited by 113
miR-320a mediates doxorubicin-induced cardiotoxicity by targeting VEGF signal pathway
Yin, Z., Zhao, Y., Li, H., Yan, M., Zhou, L., Chen, C., & Wang, D. W. (2016) · Aging · doi:10.18632/aging.100876 · Cited by 103
Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells
Zhang, Z., Lin, G., Yan, Y., Li, X., Hu, Y., Wang, J., Yin, B., Wu, Y., Li, Z., & Yang, X. (2018) · Oncogene · doi:10.1038/s41388-018-0221-4 · Cited by 102
Sonowal, H., Pal, P. B., Wen, J.-J., Awasthi, S., Ramana, K. V., & Sk, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-03284-w · Cited by 101
A small molecule inhibitor of PAI-1 protects against doxorubicin-induced cellular senescence
Ghosh, A. K., Rai, R., Park, K. E., Eren, M., Miyata, T., Wilsbacher, L. D., & Vaughan, D. E. (2016) · Oncotarget · doi:10.18632/oncotarget.12494 · Cited by 94
Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation
Forrest, R. A., Swift, L. P., Rephaeli, A., Nudelman, A., Kimura, K., Phillips, D. R., & Cutts, S. M. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.02.026 · Cited by 92
Chou, H., Wang, K., Chen, C., Wei, L., Lai, C., Hsieh, C., Yang, Y., Twu, N.-F., Chang, T., & Yen, M. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.10.027 · Cited by 90
Coldwell, K. E., Cutts, S. M., Ognibene, T. J., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn439 · Cited by 87
APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cells
Stefanski, C. D., Keffler, K., McClintock, S., Milac, L., & Prosperi, J. R. (2019) · Neoplasia · doi:10.1016/j.neo.2019.09.002 · Cited by 87
Testosterone Antagonizes Doxorubicin‐Induced Senescence of Cardiomyocytes
Altieri, P., Barisione, C., Lazzarini, E., Garuti, A., Bezante, G. P., Canepa, M., Spallarossa, P., Tocchetti, C. G., Bollini, S., Brunelli, C., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002383 · Cited by 86
Han, J., Lim, W., You, D., Jeong, Y., Kim, S., Lee, J. E., Shin, T. H., Lee, G., & Park, S. (2019) · Journal of Oncology · doi:10.1155/2019/1345026 · Cited by 85
Adriamycin (doxorubicin) cardiotoxicity: a review.
Chlebowski, R. T. (1979) · PubMed · Cited by 84
Edwardson, D. W., Boudreau, J., Mapletoft, J., Lannér, C., Kovala, A. T., & Parissenti, A. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183662 · Cited by 82
Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients
Speth, P. A. J., Linssen, P. C. M., Boezeman, J. B. M., Wessels, H. M. C., & Haanen, C. (1987) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00262581 · Cited by 81
Epigenetic targeting drugs potentiate chemotherapeutic effects in solid tumor therapy
Li, J., Hao, D., Wang, L., Wang, H., Wang, Y., Zhao, Z., Li, P., Deng, C., & Di, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-04406-0 · Cited by 81
Membrane transport proteins associated with drug resistance expressed in human melanoma.
Schadendorf, D., Makki, A., Stahr, C., van Dyck, A., Wanner, R. M., Scheffer, G. L., Flens, M. J., Scheper, R. J., & Henz, B. M. (1995) · Europe PMC (PubMed Central) · Cited by 80
Fan, Y.-P., Liao, J.-Z., Lu, Y.-Q., Tian, D.-A., Ye, F., Zhao, P.-X., Xiang, G.-Y., Tang, W.-X., & He, X.-X. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.03.010 · Cited by 80
Wang, C., Wang, Z., Zhao, X., Yu, F., Quan, Y., Cheng, Y., & Yuan, H. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.12.020 · Cited by 80
Khames, A., Khalaf, M. M., Gad, A. M., El‐Raouf, O. M. A., & Kandeil, M. A. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108777 · Cited by 80
Yuan, S.-J., Xu, Y., Wang, C., An, H.-C., Xu, H., Li, K., Komatsu, N., Zhao, L., & Chen, X. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0541-8 · Cited by 77
Zweier, J. L., Gianni, L., Muindi, J. R., & Myers, C. E. (1986) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(86)90181-9 · Cited by 75
Xia, W. G., Lo, C. M., Poon, R. Y. C., Cheung, T. T., Chan, A. C. Y., Chen, L., Yang, S., Tsao, G. S., & Wang, X. Q. (2017) · Oncotarget · doi:10.18632/oncotarget.16402 · Cited by 75
Velez, J. M., Miriyala, S., Nithipongvanitch, R., Noel, T., Plabplueng, C. D., Oberley, T., Jungsuwadee, P., Van Remmen, H., Vore, M., & St. Clair, D. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018005 · Cited by 73
Wennerberg, E., Sarhan, D., Carlsten, M., Kaminskyy, V. O., D’Arcy, P., Zhivotovsky, B., Childs, R. W., & Lundqvist, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28163 · Cited by 72
Saad, S., Ahmad, I., Kawish, S. M., et al. (2019) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2019.110628 · Cited by 70
Kawano, M., Tanaka, K., Itonaga, I., Iwasaki, T., Miyazaki, M., Ikeda, S., & Tsumura, H. (2016) · Oncology Letters · doi:10.3892/ol.2016.4175 · Cited by 69
Zou, Z., Zou, R., Zong, D., Shi, Y., Chen, J., Huang, J., Zhu, J., Chen, L., Bao, X., Liu, Y., et al. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13114 · Cited by 69
Hahn, G. M., Ray, G. R., Gordon, L. F., & Kallman, R. F. (1973) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/50.2.529 · Cited by 68
Tscheschner, H., Meinhardt, E., Schlegel, P., Jungmann, A., Lehmann, L., Müller, O. J., Most, P., Katus, H. A., & Raake, P. W. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215992 · Cited by 68
Alleviation of the doxorubicin-induced nephrotoxicity by fasudil in vivo and in vitro
Xiang, C., Yan, Y., & Zhang, D. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.10.002 · Cited by 67
Cardiomyocyte-specific disruption of Cathepsin K protects against doxorubicin-induced cardiotoxicity
Guo, R., Hua, Y., Ren, J. T., Bornfeldt, K., & Nair, S. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0727-2 · Cited by 66
Giuliani, F. C., & Kaplan, N. O. (1980) · PubMed · Cited by 65
TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin
Moruno-Manchon, J. F., Uzor, N.-E., Kesler, S. R., Wefel, J. S., Townley, D. M., Nagaraja, A. S., Pradeep, S., Mangala, L. S., Sood, A. K., & Tsvetkov, A. S. (2016) · Aging · doi:10.18632/aging.101144 · Cited by 64
BURADE, V. S., Bhowmick, S., Maiti, K., Zalawadia, R., Ruan, H. H., & Thennati, R. (2017) · BMC Cancer · doi:10.1186/s12885-017-3377-3 · Cited by 64
Liu, C., Hua, X., Guo, C., Yang, Z., Wang, Y., & Wang, Y. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1638182 · Cited by 58
Impact of Doxorubicin Treatment on the Physiological Functions of White Adipose Tissue
Biondo, L. A., de Lima, E. A., de Souza, C. O., Cruz, M. M., Cunha, R. D. C. D. [., Alonso‐Vale, M. I. C., Oyama, L. M., do Nascimento, C. M. O., Pimentel, G. D., dos Santos, R. V. T., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151548 · Cited by 57
Optimal schedule of methotrexate and 5-fluorouracil in human breast cancer.
Benz, C. C., Tillis, T., Tattelman, E., & Cadman, E. C. (1982) · PubMed · Cited by 55
Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy
El‐Awady, R., Hersi, F., Al-Tunaiji, H., Saleh, E., Wahab, A. H. A. A., Homssi, A. A., Suhail, M., El-Serafi, A. T., & Al‐Tel, T. H. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1046023 · Cited by 54
Tian, T., Fu, X., Lü, J., Ruan, Z., Nan, K., Yao, Y., & Yang, Y. (2018) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22167 · Cited by 54
Rudnick‐Glick, S., Corem‐Salkmon, E., Grinberg, I., & Margel, S. (2016) · Journal of Nanobiotechnology · doi:10.1186/s12951-016-0233-6 · Cited by 52
Ameliorative effects of sildenafil and/or febuxostat on doxorubicin-induced nephrotoxicity in rats
Khames, A., Khalaf, M. M., Gad, A. M., & El‐Raouf, O. M. A. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.02.046 · Cited by 51
Grant, C. E., Gao, M., DeGorter, M. K., Cole, S. P. C., & Deeley, R. G. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.022491 · Cited by 50
Bladé, J., Sonneveld, P., Miguel, J. F. S., Sutherland, H. J., Hájek, R., Nagler, A., Spencer, A. G., Robak, T., Lantz, K. C., Zhuang, S. H., et al. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2011.n.005 · Cited by 44
Zhou, Y. F., Gottesman, M. M., & Pastan, I. H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1450 · Cited by 42
Lack of Effect of Coenzyme Q10 on Doxorubicin Cytotoxicity in Breast Cancer Cell Cultures
Greenlee, H., Shaw, J., Lau, Y.-K. I., Naini, A., & Maurer, M. (2012) · Integrative Cancer Therapies · doi:10.1177/1534735412439749 · Cited by 41
Dai, X., Mao, F., Li, S., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.7007 · Cited by 40
Hou, J., Jeon, B.-M., Yun, Y. J., Cui, C.-H., & Kim, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051244 · Cited by 40
Hu, J., Zhu, S., Xia, X., Zhang, L., Kleinerman, E. S., & Li, S. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-34 · Cited by 38
Yao, M., Ma, X., Zhang, X., Shi, L., Liu, T., Liang, X., Zhao, H., Li, X., Li, L., Gao, H., et al. (2019) · Theranostics · doi:10.7150/thno.29989 · Cited by 38
Cytotoxicity of adriamycin to tumour cells in vivo and in vitro
Martin, W. M., & McNally, N. J. (1980) · British Journal of Cancer · doi:10.1038/bjc.1980.336 · Cited by 36
Fan, Y., Li, M., Ma, K., Hu, Y., Jing, J., Shi, Y., Li, E., & Dong, D. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1539290 · Cited by 34
Gong, Y., Wu, X., Wang, T., Zhao, J., Liu, X., Yao, Z., Zhang, Q., & Xu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.17117 · Cited by 33
Liu, X., Qiu, Y., Liu, Y., Huang, N., Hua, C., Wang, Q., Wu, Z., Lu, J., Song, P., Xu, J., et al. (2020) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22639 · Cited by 33
Inoue, S., Setoyama, Y., & Odaka, A. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.1489 · Cited by 32
Heterogeneous responses of an in vitro model of human stomach cancer to anticancer drugs
BARRANCO, S. C., Townsend, C. M., Quraishi, M. A., Burger, N. L., Nevill, H. C., Howell, K. H., & Boerwinkle, W. R. (1983) · Investigational New Drugs · doi:10.1007/bf00172070 · Cited by 32
Li, S., Yang, F., Kumagai, A., Kawakita, E., Kitada, M., Kanasaki, K., & Koya, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030805 · Cited by 32
Wang, Y., Liu, M., Zhang, J., Liu, Y., Kopp, M., Zheng, W., & Xiao, S. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy038 · Cited by 27
Gao, Z., Li, Z., Liu, Y., & Liu, Z. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.554 · Cited by 21
Mei, Y., Liao, X., Zhu, L., & Yang, H. (2020) · The Journal of Biochemistry · doi:10.1093/jb/mvaa009 · Cited by 20
Vijayaraghavalu, S., & Labhasetwar, V. D. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0556-y · Cited by 19
Panchuk, R. R., Skorokhyd, N. R., Kozak, Y., Lehka, L., Мойсеенок, А. Г., & Stoika, R. S. (2017) · Croatian Medical Journal · doi:10.3325/cmj.2017.58.171 · Cited by 15
Evaluation of age effects on doxorubicin-induced toxicity in mesenchymal stem cells
Dezfouli, A. B., Pourfathollah, A. A., Amoli, J. S., Khosravi, M., Nikogoftar-Zarif, M., Yazdi, M., & Ali-Esfahani, T. (2017) · Medical Journal of the Islamic Republic of Iran · doi:10.14196/mjiri.31.98 · Cited by 12
Mutlu, P., Azarkan, S. Y., Pourianazar, N. T., Yücel, M., & Gündüz, U. (2018) · EXCLI journal · doi:10.17179/excli2018-1129 · Cited by 10
Gonzalez‐Fajardo, L., Ndaya, D. M., Kasi, R. M., & Lü, X. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118701 · Cited by 5
Cited by
Cellular landscaping of cisplatin resistance in cervical cancer
Bhattacharjee, R., Dey, T., Kumar, L., Kar, S., Sarkar, R., Ghorai, M., Malik, S., Jha, N. K., Vellingiri, B., Kesari, K. K., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113345 · Cited by 93
Metadata
- Authors
- Sritharan, S., & Sivalingam, N.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 278
- Pages
- 119527
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W3155496868
- Cited by
- 487
- References
- 111
- FWCI
- 17.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.